Clinical Trials
23 trialsNCT00003615 2023-06-15
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT01127451 2022-04-13
Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma
Eisai Inc.
Phase 2 Completed
NCT00515528 2021-01-26
Vaccination Plus Ontak in Patients With Metastatic Melanoma
University of Chicago
Phase 2 Terminated
NCT00632827 2020-04-27
Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)
University of California, San Francisco
Phase 2 Terminated
NCT00211185 2020-03-18
A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma
Eisai Inc.
Phase 2 Completed
NCT00117845 2019-11-19
Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01773889 2018-04-10
A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A in Stage III or IV Ovarian Cancer
The University of Texas Health Science Center at San Antonio
Phase 2 Terminated
NCT00880360 2018-03-27
ONTAK
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
NCT01106950 2017-12-28
Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT00460109 2017-04-18
Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00082940 2017-01-19
Denileukin Diftitox in Treating Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia
Wake Forest University Health Sciences
Phase 2 Completed
NCT00726037 2016-09-29
A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer
Loyola University
Phase 2 Terminated
NCT00337987 2015-02-27
A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma
Yale University
Phase 2 Completed
NCT00299689 2014-09-05
Phase II Trial of Ontak With Metastatic Melanoma
James Graham Brown Cancer Center
Phase 2 Completed
NCT00026429 2013-12-18
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00082914 2013-06-20
Denileukin Diftitox in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00006345 2013-05-30
Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00138164 2013-05-30
Denileukin Diftitox in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00801918 2013-05-15
Denileukine Diftitox for Relapsed ALCL
Columbia University
Phase 2 Withdrawn
NCT00051025 2012-07-13
Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin's Lymphoma (NHL)
Eisai Inc.
Phase 2 Completed
NCT00211276 2012-03-14
A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma
Eisai Inc.
Phase 2 Completed
NCT00493129 2012-02-08
Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00055146 2009-04-17
Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL)
Eisai Inc.
Phase 2 Completed